253 related articles for article (PubMed ID: 28802188)
1. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA;
Eur J Cancer; 2017 Oct; 84():114-120. PubMed ID: 28802188
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
3. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
[TBL] [Abstract][Full Text] [Related]
4. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
5. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
7. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
8. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
[TBL] [Abstract][Full Text] [Related]
10. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
12. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
14. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
[TBL] [Abstract][Full Text] [Related]
15. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
Iqbal J; Nussenzweig A; Lubinski J; Byrski T; Eisen A; Bordeleau L; Tung NM; Manoukian S; Phelan CM; Sun P; Narod SA;
Br J Cancer; 2016 May; 114(10):1160-4. PubMed ID: 26986251
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
17. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
[TBL] [Abstract][Full Text] [Related]
18. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
19. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.
Duffy DL; Antill YC; Stewart CJ; Young JP; ; Spurdle AB
Twin Res Hum Genet; 2011 Apr; 14(2):111-8. PubMed ID: 21425892
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]